Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Middleton

Showing results (431-440 of 522) with videos related to

Pageof 53
Sort By:
Mbio|May 19, 2021
Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphilaBradford Becken, Lauren Davey, Dustin R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaM R Middleton, P Friedlander, O Hamid, et al.
BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.
Oncotarget|October 27, 2015
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomideRoger Ramcharan, Tamara Aleksic, Wilfride Petnga Kamdoum, et al.
Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
British Journal of Cancer|April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatribA J Watson, M R Middleton, G McGown, et al.
Radiology|January 16, 2019
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I TrialMichael D Gray, Paul C Lyon, Christophoros Mannaris, et al.
Pageof 53

Showing results (431-440 of 522) with videos related to

Sort By:
Pageof 53
Mbio|May 19, 2021
Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphilaBradford Becken, Lauren Davey, Dustin R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaM R Middleton, P Friedlander, O Hamid, et al.
BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.
Oncotarget|October 27, 2015
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomideRoger Ramcharan, Tamara Aleksic, Wilfride Petnga Kamdoum, et al.
Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
British Journal of Cancer|April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatribA J Watson, M R Middleton, G McGown, et al.
Radiology|January 16, 2019
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I TrialMichael D Gray, Paul C Lyon, Christophoros Mannaris, et al.
Pageof 53